These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

475 related items for PubMed ID: 26209543

  • 1. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy.
    Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM, Cerda J, Carter B, Jung B, Hernandez G, Gipson D, Wyatt RJ.
    Am J Kidney Dis; 2015 Nov; 66(5):783-91. PubMed ID: 26209543
    [Abstract] [Full Text] [Related]

  • 2. A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616].
    Hogg RJ, Wyatt RJ, Scientific Planning Committee of the North American IgA Nephropathy Study.
    BMC Nephrol; 2004 Mar 25; 5():3. PubMed ID: 15043759
    [Abstract] [Full Text] [Related]

  • 3. Mycophenolate Mofetil Combined With Prednisone Versus Full-Dose Prednisone in IgA Nephropathy With Active Proliferative Lesions: A Randomized Controlled Trial.
    Hou JH, Le WB, Chen N, Wang WM, Liu ZS, Liu D, Chen JH, Tian J, Fu P, Hu ZX, Zeng CH, Liang SS, Zhou ML, Zhang HT, Liu ZH.
    Am J Kidney Dis; 2017 Jun 25; 69(6):788-795. PubMed ID: 28215945
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of Mycophenolate Mofetil Among Patients With Progressive IgA Nephropathy: A Randomized Clinical Trial.
    Hou FF, Xie D, Wang J, Xu X, Yang X, Ai J, Nie S, Liang M, Wang G, Jia N, MAIN Trial Investigators.
    JAMA Netw Open; 2023 Feb 01; 6(2):e2254054. PubMed ID: 36745456
    [Abstract] [Full Text] [Related]

  • 5. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial.
    Frisch G, Lin J, Rosenstock J, Markowitz G, D'Agati V, Radhakrishnan J, Preddie D, Crew J, Valeri A, Appel G.
    Nephrol Dial Transplant; 2005 Oct 01; 20(10):2139-45. PubMed ID: 16030050
    [Abstract] [Full Text] [Related]

  • 6. Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.
    Dussol B, Morange S, Burtey S, Indreies M, Cassuto E, Mourad G, Villar E, Pouteil-Noble C, Karaaslan H, Sichez H, Lasseur C, Delmas Y, Nogier MB, Fathallah M, Loundou A, Mayor V, Berland Y.
    Am J Kidney Dis; 2008 Oct 01; 52(4):699-705. PubMed ID: 18585835
    [Abstract] [Full Text] [Related]

  • 7. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
    Li P, Chen YZ, Lin HL, Ni ZH, Zhan YL, Wang R, Yang HT, Fang JA, Wang NS, Li WG, Sun XF, Chen XM.
    Trials; 2017 Apr 11; 18(1):170. PubMed ID: 28395659
    [Abstract] [Full Text] [Related]

  • 8. Long-term study of mycophenolate mofetil treatment in IgA nephropathy.
    Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN.
    Kidney Int; 2010 Mar 11; 77(6):543-9. PubMed ID: 20032964
    [Abstract] [Full Text] [Related]

  • 9. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study.
    Maes BD, Oyen R, Claes K, Evenepoel P, Kuypers D, Vanwalleghem J, Van Damme B, Vanrenterghem YF.
    Kidney Int; 2004 May 11; 65(5):1842-9. PubMed ID: 15086925
    [Abstract] [Full Text] [Related]

  • 10. Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children.
    Kang Z, Li Z, Duan C, Wu T, Xun M, Ding Y, Zhang Y, Zhang L, Yin Y.
    Pediatr Nephrol; 2015 Jul 11; 30(7):1121-9. PubMed ID: 25773534
    [Abstract] [Full Text] [Related]

  • 11. Immunosuppressive agents for treating IgA nephropathy.
    Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA, Molony DA, Schena FP, Strippoli GF.
    Cochrane Database Syst Rev; 2015 Aug 03; (8):CD003965. PubMed ID: 26235292
    [Abstract] [Full Text] [Related]

  • 12. [A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy].
    Chen X, Chen P, Cai G, Wu J, Cui Y, Zhang Y, Liu S, Tang L.
    Zhonghua Yi Xue Za Zhi; 2002 Jun 25; 82(12):796-801. PubMed ID: 12126522
    [Abstract] [Full Text] [Related]

  • 13. Short-term anti-proteinuric effect of tacrolimus is not related to preservation of the glomerular filtration rate in IgA nephropathy: A 5-year follow-up study.
    Yu MY, Kim YC, Koo HS, Chin HJ.
    PLoS One; 2017 Jun 25; 12(11):e0188375. PubMed ID: 29155873
    [Abstract] [Full Text] [Related]

  • 14. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.
    Liu LJ, Yang YZ, Shi SF, Bao YF, Yang C, Zhu SN, Sui GL, Chen YQ, Lv JC, Zhang H.
    Am J Kidney Dis; 2019 Jul 25; 74(1):15-22. PubMed ID: 30922594
    [Abstract] [Full Text] [Related]

  • 15. Treatment of Patients with IgA Nephropathy: Evaluation of the Safety and Efficacy of Mycophenolate Mofetil.
    Chen Z, Chen W, Zheng L, Xie Y, Yao K, Zhou T.
    Curr Pharm Des; 2024 Jul 25; 30(30):2400-2409. PubMed ID: 38988169
    [Abstract] [Full Text] [Related]

  • 16. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.
    Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L, NEFIGAN Trial Investigators.
    Lancet; 2017 May 27; 389(10084):2117-2127. PubMed ID: 28363480
    [Abstract] [Full Text] [Related]

  • 17. Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment.
    Beckwith H, Medjeral-Thomas N, Galliford J, Griffith M, Levy J, Lightstone L, Palmer A, Roufosse C, Pusey C, Cook HT, Cairns T.
    Nephrol Dial Transplant; 2017 Jan 01; 32(suppl_1):i123-i128. PubMed ID: 28391339
    [Abstract] [Full Text] [Related]

  • 18. Mycophenolate mofetil in the treatment of IgA nephropathy: a systematic review.
    Tan CH, Loh PT, Yang WS, Chan CM.
    Singapore Med J; 2008 Oct 01; 49(10):780-5. PubMed ID: 18946610
    [Abstract] [Full Text] [Related]

  • 19. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
    Weiss RJ, Stapff M, Lin Y.
    Am J Cardiovasc Drugs; 2013 Apr 01; 13(2):129-40. PubMed ID: 23519546
    [Abstract] [Full Text] [Related]

  • 20. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy.
    Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S.
    Hypertens Res; 2004 Dec 01; 27(12):963-70. PubMed ID: 15894837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.